Theravance Biopharma's Phase 3 CYPRESS Study Fails Primary Endpoint, Company Winds Down Ampreloxetine Program
核心洞察
Theravance Biopharma's Phase 3 CYPRESS study evaluating ampreloxetine for neurogenic orthostatic hypotension (搜索) in multiple system atrophy (搜索) patients failed to meet its primary endpoint, leading to program termination.
The company is implementing a 60% cost reduction through organizational restructuring, including complete R&D wind-down and 50% workforce reduction, expected to save approximately $70 million annually.
Theravance's Strategic Review Committee is accelerating evaluation of value-maximizing alternatives, including potential company sale, while focusing on YUPELRI (搜索) as its core commercial asset.
Theravance Biopharma Inc. announced that its Phase 3 CYPRESS study evaluating ampreloxetine for symptomatic neurogenic orthostatic hypotension (搜索) (nOH) due to multiple system atrophy (搜索) (MSA) failed to meet its primary endpoint. The disappointing results have prompted the company to wind down the ampreloxetine program entirely and accelerate strategic alternatives to maximize shareholder value.
The CYPRESS study did not achieve statistical significance in its primary endpoint, the change in Orthostatic Hypotension Symptom Assessment (OHSA) composite score at Week 8 during the double-blind randomized withdrawal period. Similar trends were observed across secondary endpoints at week 8. Despite the clinical failure, changes in blood pressure, heart rate and norepinephrine levels confirmed ampreloxetine's biological activity, and the drug was generally well tolerated with safety findings consistent with prior studies.
Strategic Response and Organizational Restructuring
Following the clinical setback, Theravance Biopharma's Strategic Review Committee is accelerating its ongoing evaluation of value-maximizing alternatives, including a potential sale of the company. The committee, working with independent financial advisor Lazard, has been evaluating opportunities since its formation in 2024 under multiple potential CYPRESS study outcomes.
"We are disappointed that ampreloxetine did not meet the primary endpoint in the CYPRESS study," said Rick E Winningham, Chief Executive Officer of Theravance Biopharma. "Given these results, we are taking decisive steps to restructure the organization and significantly reduce our cost base, which we expect will allow YUPELRI (搜索) to drive meaningful and sustainable cash flow for the company."
The company is implementing comprehensive organizational restructuring expected to reduce operating expenses by approximately 60%, relative to 2025 preliminary actuals of approximately $110 million. The restructuring will impact approximately 50% of the overall workforce, including complete wind-down of the R&D organization and a 50% reduction in general and administrative employees. These actions will be implemented over the next two quarters, with the company expecting to incur approximately $5 to $7 million in one-time cash severance costs.
Financial Position and YUPELRI Performance
The cost savings from restructuring, combined with continued YUPELRI (搜索) sales, are expected to generate approximately $60 to $70 million of annualized cash flow starting in Q3 2026. This projection comprises an estimated $45 to $55 million of Income from Operations (excluding non-cash share-based compensation) and projected Interest and Other Income.
YUPELRI (搜索) (revefenacin) inhalation solution, the first and only once-daily, nebulized long-acting muscarinic antagonist (搜索) (LAMA) bronchodilator approved in the U.S. for COPD (搜索) maintenance treatment, continues to show strong commercial performance. The drug achieved quarterly U.S. net sales of $70.6 million in Q4 2025, representing 6% year-over-year growth. Annual U.S. net sales reached $266.6 million, increasing 12% year-over-year and triggering a $25 million sales-based milestone from Viatris.
Strong Balance Sheet Despite Setback
Theravance Biopharma maintains a robust financial position with cash totaling $326.5 million as of December 31, 2025, with no debt. The company received a $25 million YUPELRI (搜索) U.S. sales milestone from Viatris in January 2026 and a $50 million TRELEGY milestone from Royalty Pharma (搜索) in February 2026. After receiving these milestones in Q1 2026, the company expects approximately $400 million in cash at the end of Q1 2026.
Additional value drivers include the company's 35% interest in YUPELRI (搜索) that generates durable cash flow with intellectual property protection in the U.S. into 2039, and a potential $100 million TRELEGY milestone payment expected in 2026 based on GSK's reported FY 2025 global TRELEGY net sales of approximately $3.91 billion.
Future Regulatory Considerations
While winding down the ampreloxetine program, Theravance will complete additional analyses of the CYPRESS dataset and Phase 3 program in consultation with external experts to assess whether the data merits further regulatory discussion. This assessment aims to provide the Strategic Review Committee with additional clarity regarding any remaining value in ampreloxetine for shareholders, though there is no assurance that additional regulatory engagement will occur.
Susannah Gray, independent Chair of the Board and Chair of the Strategic Review Committee, emphasized the committee's commitment: "The Committee was established with a clear mandate to deliver maximum value to Theravance Biopharma shareholders, and the Committee is squarely focused on acting with urgency and discipline to ensure that we achieve the best outcome for shareholders."